Analyst Ratings for Biogen
Portfolio Pulse from Benzinga Insights
In the last quarter, Biogen (NASDAQ:BIIB) received 23 ratings from analysts, with 12 being bullish, 8 somewhat bullish, and 3 indifferent. The company has an average 12-month price target of $331.48, which has increased by 1.87% over the past month.
July 26, 2023 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biogen received mostly bullish ratings from analysts, which could positively impact its stock price. The increase in the average price target also suggests potential upside.
Analyst ratings often influence investor sentiment and can impact a stock's price. The majority of the ratings for Biogen are bullish, which is positive for the stock. Additionally, the increase in the average price target suggests analysts see potential for the stock's price to rise.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100